Esra ATAOĞLU, Macit KOLDAŞ, Evrim ÇAKIR, Mustafa YENİGÜN, Süleyman AHBAB, Yasemin ERDOĞAN DÖVENTAŞ, Alp ATASOY

Visfatin levels in hormonally inactive adrenal adenoma and their association with metabolic parameters

Background/aim: In parallel with increased frequency and higher quality of imaging techniques, the prevalence of adrenal adenomahas gradually increased. However, despite the growing incidence, the metabolic and tumorigenesis processes involved in its etiology arestill unclear. Although visfatin has been reported to be associated with inflammation and tumorigenesis, its role in adrenal adenoma hasnot yet been investigated. Therefore, the present study was performed with an aim to evaluate visfatin levels and cardiometabolic riskfactors in patients with adrenal adenoma.Materials and methods: Thirty patients recently diagnosed with adrenal adenoma along with 30 healthy participants were studied in atertiary healthcare center. Twenty-four-hour ambulatory blood pressure monitoring and carotid artery intima-media thickness (CIMT)measurements were performed.Results: The frequencies of diabetes mellitus and hypertension were found to be statistically higher in the adrenal adenoma group.Although the values of mean fasting glucose, insulin, HOMA-IR levels, and the mean, maximum, minimum, delta systolic, and diastolicblood pressures were established to be higher in the adrenal adenoma group, the differences were not found to be statistically significant.Mean high-sensitive C-reactive protein, visfatin levels, and CIMT were seen to be significantly higher in the adenoma group.Conclusion: Cardiometabolic risk factors as well as the visfatin levels were established to be higher in patients with adrenal adenoma.Elevated visfatin levels might play a role in the development and metabolic process of adrenal adenoma.

PDF

___

Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994; 14: 1431-1437.
Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-1758.
Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 2007; 23: 164-170.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
Tuna MM, Imga NN, Dogan BA, Yilmaz FM, Topcuoglu C, Akbaba G, Berker D, Guler S. Non-functioning adrenal incidentalomas are associated with higher hypertension prevalence and higher risk of atherosclerosis. J Endocrinol Invest 2014; 37: 765-768.
Peppa M, Boutati E, Koliaki C, Papaefstathiou N, Garoflos E, Economopoulos T, Hadjidakis D, Raptis SA. Insulin resistance and metabolic syndrome in patients with nonfunctioning adrenal incidentalomas: a cause-effect relationship? Metabolism 2010; 59: 1435-1441.
Yener S, Genc S, Akinci B, Secil M, Demir T, Comlekci A, Ertilav S, Yesil S. Carotid intima media thickness is increased and associated with morning cortisol in subjects with nonfunctioning adrenal incidentaloma. Endocrine 2009; 35: 365- 370.
Comlekci A, Yener S, Ertilav S, Secil M, Akinci B, Demir T, Kebapcilar L, Bayraktar F, Yesil S, Eraslan S. Adrenal incidentaloma, clinical, metabolic, follow-up aspects: single centre experience. Endocrine 2010; 37: 40-46.
Arruda M, Mello Ribeiro Cavalari E, Pessoa de Paula M, Fernandes Cordeiro de Morais F, Furtado Bilro G, Alves Coelho MC, de Oliveira E Silva de Morais NA, Choeri D, Moraes A, Vieira Neto L. The presence of nonfunctioning adrenal incidentalomas increases arterial hypertension frequency and severity, and is associated with cortisol levels after dexamethasone suppression test. J Hum Hypertens 2017; 32: 3-11.
Androulakis II, Kaltsas GA, Kollias GE, Markou AC, Gouli AK, Thomas DA, Alexandraki KI, Papamichael CM, Hadjidakis DJ, Piaditis GP. Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. J Clin Endocrinol Metab 2014; 99: 2754-2762.
Yener S, Comlekci A, Akinci B, Secil M, Demir T, Ertilav S, Yesil S. Non-functioning adrenal incidentalomas are associated with elevated D-dimer levels. J Endocrinol Invest 2009; 32: 338-343.
Nergiz Avcioglu S, Altinkaya SO, Kucuk M, Yuksel H, Omurlu IK, Yanik S. Visfatin concentrations in patients with endometrial cancer. Gynecol Endocrinol 2015; 31: 202-207.
Kim JG, Kim EO, Jeong BR, Min YJ, Park JW, Kim ES, Namgoong IS, Kim YI, Lee BJ. Visfatin stimulates proliferation of MCF-7 human breast cancer cells. Mol Cells 2010; 30: 341- 345.
Bi TQ, Che XM. Nampt/PBEF/visfatin and cancer. Cancer Biol Ther 2010; 10: 119-125.
Park HJ, Kim SR, Kim SS, Wee HJ, Bae MK, Ryu MH, Bae SK. Visfatin promotes cell and tumor growth by upregulating Notch1 in breast cancer. Oncotarget 2014; 5: 5087-5099.
Neubauer K, Misa IB, Diakowska D, Kapturkiewicz B, Gamian A, Krzystek-Korpacka M. Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1β, and anemia. Biomed Res Int 2015; 2015: 523930.
Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, Erdem G, Gok M, Bingol N, Kilic S et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007; 76: 24-29.
Ahmed MB, Ismail MI, Meki AR. Relation of osteoprotegerin, visfatin and ghrelin to metabolic syndrome in type 2 diabetic patients. Int J Health Sci (Qassim) 2015; 9: 127-139.
Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007; 30: 323-326.
Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y, Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008; 69: 878-884.
Gen R, Akbay E, Muslu N, Sezer K, Cayan F. Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance. Gynecol Endocrinol 2009; 25: 241-245.
Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Bluher M. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-2916.
Lan J, Chen X, Chen X, Wang S, Zhang X, Wu K, He S, Peng Y, Jiang L, Li L et al. The relationship between visfatin and HOMAIR in hypertensive patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in hypertensive patients with insulin resistance. Diabetes Res Clin Pract 2011; 94: 71-76.
Xu XF, Wu M. Nicotinamide phosphoribosyltransferase and its roles in cancer. Zhejiang Da Xue Xue Bao Yi Xue Ban 2014; 43: 109-114 (in Chinese with abstract in English).